DocWire News Editors

DocwireNews

According to research presented at the <a href="https://www.sgo50.org/abstract-submission-3/">2019 Society of Gynecologic Oncology Annual Meeting</a>, there were no significant differences in outcomes based on age among recurrent ovarian carcinoma patients taking rucaparib. The study analyzed data from ARIEL3, a randomized, placebo-controlled study in which patients randomized 2:1 received either oral rucaparib (600 BID) or placebo. The researchers stratified patients into three subgroups based on patient age at baseline&mdash;&lt; 65 years, 65-74 years, or &ge; 75 years&mdash;and evaluated progression-free survival (PFS) and safety. Efficacy and safety visit cutoff dates were April 15, 2017, and Aug. 15, 2017, respectively.The age &lt; 65 years group had more patients with a deleterious germline or somatic BRCA mutation (rucaparib, n = 96 [40.5%]; placebo, n = 49 [41.9%]) compared to the 65-74 years (rucaparib, n = 29 [25.7%]; placebo, n = 15 [23.4%]) and &ge; 75 years (rucaparib, n = 5 [20.0%]; placebo, n = 2 [25.0%]) groups. Median PFS in the patient age &lt; 65 years group was 11.1 months (n = 237) in the rucaparib group compared to 5.4 months (n = 117) among placebo patients (hazard ratio [HR] = 0.33; 95% confidence interval [CI] 0.25&ndash;0.43). In the age 65-74 years cohort, median PFS was 8.3 months (n = 113) versus 5.3 months, respectively (n = 64; HR = 0.43; 95% CI 0.29&ndash;0.64). In the age &ge; 75 years cohort, median PFS was 9.2 months (n = 25) versus 5.5 months, respectively (n = 8; HR = 0.47; 95% CI 0.16&ndash;1.35). The most common treatment-emergent adverse events (TEAEs) in the treatment arm of all three subgroups were nausea and asthenia. The most common hematologic TEAEs in rucaparib patients in all three groups included anemia and thrombocytopenia.The authors concluded that maintenance rucaparib treatment was associated with better PFS and progression outcomes compared to placebo, with a similar safety profile regardless of age. They also noted that dose modification and treatment discontinuation trends differed across the subgroups, without a clear trend emerging.Ledermanna JA, Ozab AM, Lorusso D, et al. The effect of age on efficacy and safety outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase III, randomized, placebo-controlled maintenance study in patients with recurrent ovarian carcinoma.

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Latest News

Rucaparib Safe Regardless of Age

Spring 2019 Conference coverage

2019 Society of Gynecologic Oncology Annual Meeting, there were no significant differences in outcomes based on age among recurrent ovarian carcinoma patients taking ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe